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Antimetastatic Properties of Low
Molecular Weight Heparin
TO THE EDITOR: The well-performed and important FRAG-
MATIC (Dalteparin in Preventing Blood Clots in Patients With
Lung Cancer) trial reported by Macbeth et al1 concluded that the
addition of prophylactic doses of the lowmolecular weight heparin
(LMWH) dalteparin for 24 weeks to standard of care in patients
with lung cancer did not improve overall survival; the rate of
venous thromboembolism was signiﬁcantly reduced but at the cost
of an increase in bleeding complications. There was also no
signiﬁcant effect on metastasis in the group that received dalteparin.
Although the results are important for this particular clinical situation,
we are concerned that generalization of the concept that LMWHs do
not have antitumor or antimetastatic effects could hamper further
development of effective treatment algorithms, including LMWHs,
for patients with cancer.
Heparins are highly sulfated glycosaminoglycans, and we pre-
viously reported the impact of heparins (in particular, tinzaparin)
in preclinical models2,3 that demonstrated strong inhibition of tumor
colonization via interference with binding of P- and L-selectin
to cancer mucins.2,4 Of note, dalteparin is not a good inhibitor
of selectin-mediated interactions compared with tinzaparin and
unfractionated heparin.5 Tinzaparin or unfractionated heparin have
higher negative charge and longer chains of glycosaminoglycans and
thus they may be favored over dalteparin as antimetastatic agents.5
Heparin inhibition of P-selectin–mediated interactions reduced
platelet binding to mucins on tumor cells, increased immune-
mediated clearing during hematogenous dissemination,2 and blocked
L-selectin–mediated recruitment of monocytes required for tumor
cell extravasation and organ colonization.4,6
Although the authors should be congratulated for having
chosen overall survival (and not only the occurrence of venous
thromboembolism) as an end point, the FRAGMATIC trial was not
designed to examine the antimetastatic properties of LMWHs.1
Studies that test LMWHs with better antimetastatic properties such
as tinzaparin should be conducted in a setting clearly deﬁned for
preventing metastasis. The best environment for testing an anti-
metastatic agent would be localized cancers that are being deﬁnitively
treated by surgery or radiation together with chemotherapy. Trials that
test tinzaparin in the adjuvant or perioperative setting for pa-
tients with lung cancer (eg, NCT00475098; Effect of Low Mo-
lecular Weight Heparin: Tinzaparin in Lung Tumours [TILT])
and resectable cancer of the colon (eg, NCT01455831; Extended
Peri-operative Tinzaparin to Improve Disease-Free Survival in
Patients With Resectable Colorectal Cancer [PERIOP-01]) are
ongoing. They are better suited for answering questions about
the antimetastatic properties of LMWHs.
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